Summary
According to post hoc analyses of the Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes [BARI 2D; NCT00006305] data, rosiglitazone is not associated with an increased risk of major adverse cardiovascular events, including myocardial infarction and death, in patients with type 2 diabetes mellitus and established coronary artery disease.
- Interventional Techniques & Devices
- Diabetes Mellitus
- Coronary Artery Disease
- Diabetes & Endocrinology Clinical Trials
- © 2010 MD Conference Express
Tools
Table of contents
Cited By...
- No citing articles found.